Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of AKP-009 single and multiple oral doses in healthy male volunteers
jRCT2071210062Phase 1Completed
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ludaterone acetate in benign prostatic hyperplasia (BPH) (6 arms), sponsored by ASKA Pharmaceutical Holdings Co., Ltd. Primary endpoints: Pharmacokinetics of AKP-009 and Safety and tolerability. Started Oct 2021; status: completed.
02
Drugs
ludaterone acetate
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on jRCT2071210062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210062.